[go: up one dir, main page]

WO1999066060A1 - Promoteur du gene humain mp52 et procede l'associant dans la recherche de substances utiles - Google Patents

Promoteur du gene humain mp52 et procede l'associant dans la recherche de substances utiles Download PDF

Info

Publication number
WO1999066060A1
WO1999066060A1 PCT/IB1999/001071 IB9901071W WO9966060A1 WO 1999066060 A1 WO1999066060 A1 WO 1999066060A1 IB 9901071 W IB9901071 W IB 9901071W WO 9966060 A1 WO9966060 A1 WO 9966060A1
Authority
WO
WIPO (PCT)
Prior art keywords
human
substance
exploring
activity
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1999/001071
Other languages
English (en)
Inventor
Shinji Kawai
Takeyuki Sugiura
Gertrud Hötten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Sanofi Aventis KK
Original Assignee
Aventis Pharma Ltd
Nippon Hoechst Marion Roussel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Ltd, Nippon Hoechst Marion Roussel Ltd filed Critical Aventis Pharma Ltd
Priority to AU40542/99A priority Critical patent/AU4054299A/en
Priority to EP99923787A priority patent/EP1086238A1/fr
Priority to JP2000554869A priority patent/JP2002518019A/ja
Publication of WO1999066060A1 publication Critical patent/WO1999066060A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Definitions

  • the present invention relates to a 5 ' upstream region DNA sequence which contains a promoter of human P52 gene. Furthermore, the present invention provides a method for exploring low molecular weight compound regulating positively or negatively the expression of human MP52 by using a mass of animal cells transfected with a recombinant expression vector harboring the 5 ' upstream region DNA containing the human MP52 gene promoter in front of a suitable reporter gene, and by using a reporter activity as an indicator.
  • BMP bone morphogenetic protein
  • TGF transforming growth factor
  • Human MP52 is a BMP-like protein isolated by PCR cloning (Biochem. Biophys. Res. Comm. 204, 646-652, 1994). Recombinant human MP52 has been reported as effective not only in inducing ectopic ossification, but also in curing bone deficit in an animal model (Growth Factors 13, 65-74, 1996) .
  • BMP proteins are effective in treating, and preventing various bone disorders and bone diseases.
  • the BMP proteins exist in very small quantity in nature, and for an available large quantity for therapeutic use, manufacturing a recombinant protein is necessary.
  • the present invention provides a method for exploring a substance which induces human MP52, a BMP-like protein.
  • a useful substance obtained by this exploring method can be effective in inducing expression of human MP52, a bone formation factor. Since it has a small molecular weight and the same activity as that of human MP52, it can have a very useful application.
  • the present invention provides a method for exploring a substance which inhibits expression of human MP52. In case that human MP52 relates to bone and cartilage hyperplasia, it can prevent hyperplasia by inhibiting the expression of human MP52.
  • Fig. 1 is a 3.5 kb of 5 ' upstream region of human MP52 gene and a restriction enzyme map.
  • Fig. 2 is a recombinant expression vector (pMP52L) containing a 5' upstream region of human MP52 gene.
  • Fig. 3 is a result of measuring a human MP52 promoter activity (transient expression) .
  • pGL3B means pGL3 -basic in the figure.
  • the present invention relates to a DNA whose nucleotide sequence is represented by the base sequence from No. 1 to No. 3521 in SEQ ID NO.: 1 of the Sequence Listing that encodes a human MP52 gene promoter region, or a fragment thereof.
  • SEQ ID NO.: 1 of the Sequence Listing shows a 5' upstream region sequence of the human MP52 gene.
  • the present invention relates to a method for preparing the DNA shown in SEQ ID NO.: 1 of the Sequence Listing having the steps of:
  • the plasmid vector used here is not restricted and any commercialized vector can be used.
  • a preferable example is pUC18.
  • the present invention relates to a recombinant expression vector characterized by integration of the full length or a part of DNA shown in SEQ ID NO.: 1 of the Sequence Listing into a reporter gene.
  • the recombinant expression vector is constructed to locate a suitable region of 5' upstream region of the human MP-52 gene, that is represented by SEQ ID No.: 1 of the Sequence Listing, in front of a reporter gene.
  • the reporter gene such as luciferase or ⁇ -galactosidase gene shows an expressing status on behalf of an original product.
  • the basic vector for constructing the recombination expression vector is not specially restricted to allow to use a plasmid vector commercialized.
  • the present invention uses pGL3 -basic as a preferable example.
  • the use of pGL3 -basic yielded a pMP52L (8085 bp) that is a recombination vector containing the human MP52 promoter and a luciferase reporter gene.
  • the present invention assigned it to a recombination expression vector. It is necessary to introduce the vector, to mammalian cells, preferably a human osteoblast-like cells, such as SaOS-2 cells, with a liposome.
  • the animal cells stably transfected with the recombinant expression vector are selected by using a resistance marker.
  • the present invention relates to an exploring method for a useful substance by using a recombinant expression vector characterized by integrating the full length or a part of DNA shown in SEQ ID NO. : 1 of the Sequence Listing into a reporter gene.
  • the sequence from 2880 to 3521 in SEQ ID NO.: 1 of the Sequence Listing has been already reported (Biochem. Biophys. Res. Comm. , 204, 646-652, 1994).
  • the longer sequence has been integrated in a recombinant expression vector, the more natural process of the exploring method can be used.
  • the present invention relates to the method for exploring a useful substance which is a bone-related substance.
  • the present invention relates to the method for exploring a useful substance which is an osteogenesis inducing substance or which is an osteogenesis inhibiting substance. Furthermore, the present invention relates to the method for exploring a useful substance which is a neurogenic substance or which is an angiogenic substance.
  • a low molecular weight compound which induces or inhibits the expression of human MP52 can be obtained by isolating the promoter which regulates the expression of the gene, by ligating it to a suitable reporter gene and by introducing the gene structure into a suitable mammal cell to make an exploring system.
  • the substance which regulates the expression of human MP52 in the exploring system works on the promoter to increase or decrease the expression level of the reporter gene. Therefore, a simple and easy measurement of the reporter activity makes an exploration of the aimed possible substance.
  • the animal cell transfected with said vector can be used for a method for screening a chemical compound library by high throughput screening (Nature, 384, supp, 14-16, 1996) and finding an active substance from natural compounds.
  • the substance which increases or decreases an activity is searched by treating the cell with a compound for an appropriate period of time and measuring a reporter activity.
  • the compound obtained in such a way can regulate the expression by working directly on a transcription factor or indirectly on the promoter of human MP52 through regulating a signal transduction system. Therefore, these compounds are effective as a therapeutic agent for osteocartilaginous diseases, cancer metastasis to bone, or osteohyperplasia.
  • these compounds are effective as a recovering agent for tendon and ligament injuries, a remedy for neural diseases, or an angiogenesis inducing or inhibiting agent.
  • the substance obtained by the present invention has a bone or cartilage morphogenetic activity and is effective as an agent for therapeutic and preventive treatment in the field of orthopedic surgery (fracture, osteoarthritis such as joint osteoarthritis and hip joint osteoarthritis, arthrosteitis, damage of cartilage such as damage of meniscus, regeneration of bone and cartilage deficit caused by injury and tumor dissection, bone reconstruction such as spinal fusion and vertebral canal enlargement, and congenital cartilage and bone diseases such as dysosteogenesis and achondroplasia) , or dental fields (bone reconstruction such as palatoschisis, mandible reconstruction, and residual ridge construction), and osteoporosis.
  • the substance of the present invention can be used for bone graft in aesthetic surgery. These therapeutic treatments are effective in treating the field of veterinary surgery.
  • the present invention can provide a substance which inhibits bone or cartilage morphogenesis. In this case, the substance is applied as an agent to prevention and therapy of bone or cartilage hyperplasia.
  • the substance which induces or inhibits tendon and ligament can be obtained according to the present invention. Therefore, the present invention provides a method for exploring medicinal drugs to treat damage of tendons and ligaments. Furthermore, since human MP52 has neural cells forming, inducing, and protecting effects, the compounds obtained from the present invention can be applied as therapeutic agents for neural diseases. In addition, it is possible to obtain a substance inducing or inhibiting angiogenesis. The compounds obtained can be used as remedy for injury, carcinostatic and metastasis inhibitor.
  • low molecular weight compounds regulating positively or negatively the expression of human MP52 can be explored with reference to a reporter activity.
  • Low molecular weight compounds and their derivatives have morphogenetic activity and inhibiting activity for bone and cartilage through the expression of human MP52 and are useful as preventive or therapeutic agents for cartilage and bone diseases, remedies for osteometastasis, or therapeutic and preventive agents for osteohyperplasia. Furthermore, these compounds are effective as repairing agent for injury of tendon and ligament, therapeutic agent for neural diseases, and inducing and inhibiting agent for angiogenesis.
  • Example 1 Cloning of 5 ' upstream region of human MP52 gene The 40 cycles of PCR reaction was carried out by using the primer OD of SEQ ID No.: 2 of the Sequence Listing and the primer OID of SEQ ID No.: 3 of the Sequence Listing, cDNA derived from a human fetus (8-9 week old) as a template, and 1.5 unit Taq polymerase (provided from Perkin Elmer Cetus) . The following processes were repeated twice: the DNA amplified was treated with Sphl and AIwNI and then the PCR reaction was carried out 13 times.
  • coli pMP52 was deposited in National Institute of Bioscience and Human- Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry 1-3, Higashi 1- chome, Tsukuba-shi Ibaraki-ken 305-8566 Japan, in March 30, 1998 with depository No. FERM P-16734 and transferred to the International Depository Authority under Budapest Treaty on April 1, 1999 (Deposit No. FERM BP-6688) .
  • Example 2 Determination of DNA sequence of 5' upstream region of human MP52 gene
  • the pBluescript vector containing a human MP52 DNA of 8.8 kb was digested by Xbal , a remained large fragment (7.6 kb) was purified by agarose electrophoresis to subject to self-ligation by using a ligation kit provided from Takara Shuzo Ltd.
  • the 3.5 kb sequence of the 5' terminal was determined by using a vector containing the upstream region of the human MP52 gene of 4.7 kb as a template and by a ALF automated DNA sequencer (proviced from Amersham Pharmacia Biotech Ltd.)(Proc. Natl. Acad. Sci. USA 74, 5463-5467, 1977) .
  • the 5' upstream region of the human MP52 gene consisting of 3521 bases is presented in SEQ ID No.: 1 of the Sequence Listing. Sequencing was done at least three times. A site difficult to sequence was subcloned to sequence starting from both terminals. The base sequence from 2880 to 3521 shown in SEQ ID No.: 1 is already reported (Biochem. Biophys. Res. Comm. 204, 646-652, 1994).
  • Example 3 Construction of a recombinant vector containing the human MP52 gene promoter and a luciferase reporter gene
  • the restriction enzyme map of the 5 ' upstream region 3.5 kb of human MP52 gene is shown in Fig. 1.
  • An Apahl -Bgll fragment (0.6 kb) of the 5' upstream region of human MP52 gene was purified and the ApaLI end was blunted. Then, this fragment was treated with HindiII and Bglll and inserted into a pGL3 -basic vector of which HindiII end was blunted.
  • the vector obtained was treated with Bglll and Kpn restriction enzymes to ligate to the Bglll- pnl fragment (derived from pBluescript vector) (2.7 kb) of the 5' upstream region of the human MP52 gene.
  • the recombinant expression vector pMP52L (8085 bp) finally obtained contains 3.3 kb of 5' upstream region of human MP52 gene.
  • Fig. 2 shows the constructed recombinant expression vector.
  • Example 4 Measurement of activity of the human MP52 promoter (introduction of the recombinant expression vector into human cells and transient expression)
  • recombinant expression vector pMP52L of human MP52 promoter said vector was mixed with a vector pRL-SV40 (provided from of Pro Mega Ltd.) containing a sea pansy luciferase gene as an internal control for measurement of introducing efficiency of a gene in an equal quantity.
  • cationic liposome lipofectamine provided from Lifetech Oriental Co. was mixed with said DNA solution to add to human osteosarcoma cells;
  • said vector was mixed with a plasmid pPUR containing a gene resistant to puromycin in a proportion of 10 : 1, mixed with cationic liposome lipofectamine (provided from Lifetech Oriental Co.) and added to SaOS-2 cells for transfection.
  • the cells into which the target gene has been introduced were selected from a culture medium containing puromycin (provided from Sigma Ltd.).
  • the cells selected were inoculated in a 96-well plate, treated with substances of various chemical compound libraries for 1 - 3 days, dissolved with cytolytic agent (provided from Pro Mega Ltd.), and measured for enzyme activity by employing a luciferase assay kit (provided from Pro Mega Ltd.) .
  • cytolytic agent provided from Pro Mega Ltd.
  • luciferase assay kit provided from Pro Mega Ltd.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé de recherche de composés de faible poids moléculaire possédant une activité ostéogène ou une activité d'inhibition de l'ostéogenèse avec une performance comparable à celle des protéines morphogénétiques osseuses humaines (BMP). Ce procédé de recherche de composés de faible poids moléculaire, qui régulent positivement ou négativement l'expression du MP52 humain en référence à l'activité d'un marqueur, utilise la partie amont du gène en 5' qui contient le promoteur humain MP52 et une cellule animale dans laquelle on a introduit un vecteur d'expression recombinante préalablement lié à un gène marqueur adéquat. Des composés de faible poids moléculaire et leurs dérivés obtenus à l'aide de la présente méthode présentent, par l'expression du MP52 humain, des activités morphogénétique et inhibitrice concernant les os et les cartilages, des activités d'induction ou d'inhibition pour les tendons et les ligaments, des effets de formation, d'induction et de protection des cellules du système nerveux, ou des activités d'induction ou d'inhibition angiogénique, et sont des agents efficaces de traitement ou de prévention dans des maladies touchant les os ou les cartilages, des agents de traitement concernant les blessures aux tendons ou aux ligaments, les maladies du système nerveux, et des agents carcinostatiques ou de cicatrisation de blessure.
PCT/IB1999/001071 1998-06-18 1999-06-11 Promoteur du gene humain mp52 et procede l'associant dans la recherche de substances utiles Ceased WO1999066060A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU40542/99A AU4054299A (en) 1998-06-18 1999-06-11 Human mp52 gene promoter and method for exploring useful substance by using the same
EP99923787A EP1086238A1 (fr) 1998-06-18 1999-06-11 Promoteur du gene humain mp52 et procede l'associant dans la recherche de substances utiles
JP2000554869A JP2002518019A (ja) 1998-06-18 1999-06-11 ヒトｍｐ５２遺伝子プロモーターおよびこれを用いた有用物質の探索法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10/170941 1998-06-18
JP10170941A JP2000004882A (ja) 1998-06-18 1998-06-18 ヒトｍｐ５２遺伝子プロモーターおよびこれを用いた有用物質の探索法

Publications (1)

Publication Number Publication Date
WO1999066060A1 true WO1999066060A1 (fr) 1999-12-23

Family

ID=15914215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001071 Ceased WO1999066060A1 (fr) 1998-06-18 1999-06-11 Promoteur du gene humain mp52 et procede l'associant dans la recherche de substances utiles

Country Status (4)

Country Link
EP (1) EP1086238A1 (fr)
JP (2) JP2000004882A (fr)
AU (1) AU4054299A (fr)
WO (1) WO1999066060A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176284B2 (en) 1988-04-08 2007-02-13 Stryker Corporation Osteogenic proteins
US7811793B2 (en) 1996-12-25 2010-10-12 Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Process for preparing purified active monomer of bone-derived factor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004819A1 (fr) * 1993-08-10 1995-02-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh NOUVEAU FACTEUR DE CROISSANCE/DIFFERENCIATION DE LA FAMILLE DU TGF-β (FACTEUR TRANSFORMANT DE CROISSANCE-β)
WO1997003188A2 (fr) * 1995-07-12 1997-01-30 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Utilisation de mp52 ou de mp121 pour la therapie et la prophylaxie de maladies du systeme nerveux
WO1997004095A1 (fr) * 1995-07-24 1997-02-06 Hoechst Pharmaceuticals & Chemicals K.K. Nouvelle proteine hmw humaine mp52
WO1997015308A1 (fr) * 1995-10-23 1997-05-01 Zymogenetics, Inc. Compositions et procedes pour le traitement des deficits osseux
WO1998023740A1 (fr) * 1996-11-22 1998-06-04 Akzo Nobel N.V. Promoteur de bmp-4 et utilisation d'un tel promoteur pour selectionner des agents therapeutiques destines a la prevention et/ou au traitement de l'osteoporose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004819A1 (fr) * 1993-08-10 1995-02-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh NOUVEAU FACTEUR DE CROISSANCE/DIFFERENCIATION DE LA FAMILLE DU TGF-β (FACTEUR TRANSFORMANT DE CROISSANCE-β)
WO1997003188A2 (fr) * 1995-07-12 1997-01-30 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Utilisation de mp52 ou de mp121 pour la therapie et la prophylaxie de maladies du systeme nerveux
WO1997004095A1 (fr) * 1995-07-24 1997-02-06 Hoechst Pharmaceuticals & Chemicals K.K. Nouvelle proteine hmw humaine mp52
WO1997015308A1 (fr) * 1995-10-23 1997-05-01 Zymogenetics, Inc. Compositions et procedes pour le traitement des deficits osseux
WO1998023740A1 (fr) * 1996-11-22 1998-06-04 Akzo Nobel N.V. Promoteur de bmp-4 et utilisation d'un tel promoteur pour selectionner des agents therapeutiques destines a la prevention et/ou au traitement de l'osteoporose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOTTEN G ET AL: "Cloning and expression of recombinant human growth/differentiation factor 5", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 204, no. 2, 28 October 1994 (1994-10-28), pages 646 - 652, XP002115693 *
SAMBROOK J ET AL: "MOLECULAR CLONING: A LABORATORY MANUAL, PASSAGE", MOLECULAR CLONING, 1987, pages 2.114-2.117; 14.7-14.8, XP002115694 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176284B2 (en) 1988-04-08 2007-02-13 Stryker Corporation Osteogenic proteins
US7811793B2 (en) 1996-12-25 2010-10-12 Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Process for preparing purified active monomer of bone-derived factor

Also Published As

Publication number Publication date
JP2002518019A (ja) 2002-06-25
EP1086238A1 (fr) 2001-03-28
AU4054299A (en) 2000-01-05
JP2000004882A (ja) 2000-01-11

Similar Documents

Publication Publication Date Title
KR100214740B1 (ko) 골유도조성물
US20020123481A1 (en) C-fos induced growth factor (FIGF) and DNA encoding same
AP1329A (en) Human BMP-7 promoter and method for exploring bone-related substance by using the same.
Benson-Chanda et al. Cloning and analysis of the 5′ portion of the human type-III procollagen gene (COL3A1)
HK1045939B (en) Lim mineralization protein splice variants
Bashir et al. Analysis of the human gene encoding latent transforming growth factor-β-binding protein-2
US6475735B1 (en) Human BMP-2 promoter and method for exploring bone-related substance by using the same
WO1999066060A1 (fr) Promoteur du gene humain mp52 et procede l'associant dans la recherche de substances utiles
EP0963203A4 (fr) Gene et proteine de type tolloide d'origine mammalienne
BOUTERFA et al. Differential regulation of the human H1°‐histone‐gene transcription in human tumor‐cell lines
US6159696A (en) Isolated human BMP-4 promoter region
AU759569B2 (en) Human BMP-4 promoter and method for exploring bone-related substance by using the same
Sakaue et al. Molecular cloning and characterization of human bone morphogenic protein (BMP)-5 gene promoter
MXPA00010405A (en) Human bmp-4 promoter and method for exploring bone-related substance by using the same
CZ20004016A3 (cs) Lidský BMP-4 promotor a způsob pro výzkum substancí ovlivňujících kosti za použití tohoto promotoru
Stefanovic et al. 5 Stem-Loop of Collagen 1 (I) mRNA Inhibits Translation in Vitro but Is Required for Triple Helical Collagen Synthesis in Vivo
Jakowlew Kensington, MD 20895

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999923787

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09719925

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999923787

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1999923787

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999923787

Country of ref document: EP